Trial Profile
A Pilot Phase II Trial Of ABI-007 (A Cremophor El-Free, Protein Stabilized, Nanoparticle Paclitaxel) For The Prevention Of Vascular Access Graft Failure In Patients Undergoing Hemodialysis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 12 Mar 2012 Actual patient number is 9 according to ClinicalTrials.gov.
- 15 Jun 2011 Planned end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 06 Feb 2010 New trial record